R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Executive Director - Head of Real-World Analytics and Programming

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A PhD, DSc, DrPH, MPH, or other relevant advanced degree in epidemiology, biostatistics, health outcomes, data science, or a related scientific discipline, with at least 15 years of progressively responsible experience in real-world analytics, programming, and evidence generation within pharmaceutical or biotechnology organizations.
  • Demonstrated success leading complex real-world data and real-world evidence programs from strategy through execution, including study design, analysis, programming, reporting, and regulatory submission support.
  • Demonstrated experience building, scaling, or transforming real-world analytics, programming, or data-science capabilities, including establishing standards, processes, and cross-functional partnerships.
  • Strong expertise with real-world data sources, including claims, electronic health records, registries, omics data, and linked datasets, and analytic tools such as R, SAS, and Python.
  • Demonstrated technical knowledge of epidemiologic, biostatistical, and data-science methods.
  • Knowledge of drug and clinical development processes for genomic and targeted medicines.
  • Exceptional leadership, communication, and influence skills, with the ability to work effectively across a complex matrix and shape senior-level decisions.

Responsibilities

  • Develop and lead the real-world analytics and programming capability, setting its strategy, operating model, technical standards, and priorities to generate rigorous, decision-ready real-world evidence across the product lifecycle.
  • Partner with the Head of Epidemiology and Real-World Data Strategy to align real-world data strategy, drive methodological excellence, and optimize data use for internal decision-making and evidence generation.
  • Collaborate across global and regional Health Economics and Outcomes Research, Clinical Development, Safety, Regulatory, Medical Affairs, Market Access, Commercial Analytics and Insights, and IT to ensure analyses address priority scientific, development, and business needs.
  • Collaborate with Development Biostatistics and EU Statistics to align and ensure the quality of evidence-generation activities.
  • Set and execute the enterprise strategy and multi-year roadmap for real-world analytics and programming in support of portfolio, Clinical Development, Safety, Medical Affairs, Health Economics and Outcomes Research, and epidemiology priorities.
  • Provide leadership of the cross-functional matrix delivering Medical Affairs interventional studies.
  • Lead assessment and fit-for-purpose use of real-world data sources, including claims, electronic health records, registries, genomic and omics data, and linked datasets; advise on their strengths, limitations, and feasibility for priority scientific and business questions.
  • Provide scientific and operational leadership for real-world evidence study design, protocol development, statistical analysis planning, programming, interpretation, and final reporting.
  • Ensure evidence delivery for regulatory submissions, product value, critical development decisions, natural history studies, clinical trial design and optimization, comparative effectiveness and safety studies, healthcare resource utilization studies, post-approval safety studies, and rapid feasibility and landscape assessments.
  • Establish fit-for-purpose epidemiologic, biostatistical, and data-science methods that ensure scientific rigor, reproducibility, and alignment with global regulatory guidance and stakeholder expectations for non-interventional research.
  • Lead development and adoption of scalable programming standards, reusable analytic assets, quality-control processes, and documentation practices across real-world analytics activities.
  • Partner with IT, data engineering, and other functions to define data requirements, establish data-ingestion and curation pipelines, and enable fit-for-purpose analytics environments and data-lake capabilities.
  • Provide thought leadership in advanced analytic approaches, including causal inference, predictive modeling, and artificial intelligence and machine learning, and evaluate their appropriate use to improve evidence generation and decision-making.
  • Translate complex analyses into clear, actionable insights and recommendations for executive leadership, regulatory agencies, payers, external collaborators, and scientific audiences through reports, presentations, and publications.
  • Lead and contribute to governance, portfolio, feasibility-review, and multidisciplinary teams, ensuring real-world analytics inform high-value decisions at key development, regulatory, safety, and commercialization milestones.
  • Build and lead a high-performing, multidisciplinary team and foster a strong talent and capability-development culture.
  • Own functional resourcing, prioritization, and budget planning to ensure timely, high-quality delivery across the portfolio.

Desired Qualifications

  • Experience in oncology real-world analytics and programming.
  • A track record of publications or presentations in real-world analytics and programming, epidemiology, or data science.
  • Experience aligning real-world evidence strategy to regulatory and payer evidence planning, especially around planning and execution of post-approval safety studies.
  • Experience engaging with global regulatory authorities and interpreting evolving guidance relevant to real-world data and real-world evidence.
  • Demonstrated experience applying advanced analytic techniques, including causal inference, predictive modeling, and/or artificial intelligence and machine learning, in a life-sciences evidence-generation setting.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs